Search results
Results from the WOW.Com Content Network
Novartis AG also held 33.3 percent of the shares of Roche until 2022, however it did not exercise control over Roche. [123] Novartis also has two significant license agreements with Genentech, a Roche subsidiary. [124] One agreement is for Lucentis; [125] the other is for Xolair. [126] [122]: 239
He spent eight years working in Novartis Vaccines, and was the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17] From 2014 to 2016, he was the Global Head of Development for Novartis Pharmaceuticals.
Jimenez joined Novartis in 2007 as Division Head of Novartis Pharmaceutical and was named CEO in 2010 [7] by his predecessor and Chairman Daniel Vasella. [8]During his time at Novartis, Jimenez increasingly applied standard business metrics to pharma cash flow, purchasing and competitive bidding, confident that his experience in consumer goods would help to realize improvements in Novartis ...
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. [4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz.
In September 2013, he stepped down as Chairman of the Board of Trustees of the Novartis Foundation. [1] Under the leadership of Klaus Leisinger, the Novartis Foundation united and embodied the historical commitment to corporate philanthropy of the Basel chemical industry and earned consultative status with the UN ECOSOC.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
Jörg Reinhardt (born 11 March 1956) is a German businessman who has been the chairman of the board of directors of the Swiss pharmaceutical group Novartis AG since 2013. [1] [2] Since 2017, he has also been a member of the board of directors of the Swiss reinsurance group Swiss Re.